Ingredient or product comparison
Does GHK-Cu Help Osteoarthritis: Full Comparison
GHK-Cu peptide (subcutaneous or topical) Collagen synthesis activation, NF-κB inhibition, copper delivery to cartilage Preclinical (animal + in vitro studies only) 4–8 weeks (subjective reports; not clinically validated) $80–$150 Mechanistically plausible for
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu peptide (subcutaneous or topical)
- Collagen synthesis activation, NF-κB inhibition, copper delivery to cartilage
- Preclinical (animal + in vitro studies only)
- 4–8 weeks (subjective reports; not clinically validated)
- $80–$150
- Mechanistically plausible for cartilage repair but lacks human RCT data; consider as adjunctive only alongside proven treatments
- NSAIDs (ibuprofen, naproxen)
- COX enzyme inhibition reduces prostaglandin synthesis
- High (multiple Phase 3 RCTs, decades of use)
- 1–2 weeks
- $8–$25
- First-line therapy for OA pain management; 60–70% response rate but GI and CV risks limit long-term use
- Intra-articular corticosteroids
- Suppresses synovial inflammation via glucocorticoid receptor activation
- High (systematic reviews + meta-analyses)
- 3–7 days
- $50–$100 per injection
- Provides 4–12 weeks symptom relief; repeat injections may accelerate cartilage loss. Use sparingly
- Hyaluronic acid injections
- Viscosupplementation restores synovial fluid lubrication
- Moderate (meta-analyses show modest benefit; some controversy)
- 2–4 weeks
- $200–$600 per series
- Modest pain reduction vs placebo; benefits inconsistent across studies; insurance coverage varies
- Physical therapy + exercise
- Joint stabilization, muscle strengthening reduces abnormal loading
- High (Cochrane reviews confirm efficacy)
- 4–8 weeks
- $100–$300 per month
- Non-pharmacologic cornerstone of OA management; improves function without systemic side effects